Introduction

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide and up to recently, sorafenib was the only approved systemic treatment options. In recent years, many other treatment options have received approval for advanced HCC, including nivolumab, a Programmed-Death-1 (PD-1) inhibitor.

Areas covered

We review the current treatment landscape of HCC, an overview of the characteristics of nivolumab and current ongoing and completed trials of nivolumab.

Expert opinion

Nivolumab is generally well tolerated and has modest single-agent activity as a monotherapy in advanced HCC. Further studies are required to better explore its role as part of combination approaches, in adjuvant/neoadjuvant setting, as well as to understand the impact of sequencing of its use with other systemic therapy options.

中文翻译：

---

Nivolumab用于治疗肝细胞癌。

介绍

肝细胞癌（HCC）是全球范围内与癌症相关的死亡的主要原因之一，直到最近，索拉非尼是唯一获批的全身治疗选择。近年来，许多其他治疗方案已获得晚期HCC的批准，包括nivolumab（一种程序性死亡1（PD-1）抑制剂）。

覆盖区域

我们回顾了HCC的当前治疗情况，nivolumab的特征概述以及nivolumab的当前正在进行和已完成的试验。

专家意见

通常，Nivolumab的耐受性良好，作为晚期HCC的单一疗法，其单药活性中等。需要进行进一步的研究，以更好地探索其在佐剂/新佐剂环境中作为联合疗法的一部分的作用，以及了解其使用顺序与其他全身疗法的影响。